Management strategies in advanced RCC

Dr. Aly-Khan Lalani is joined by Dr. David Braun and Dr. Bradley McGregor for a virtual roundtable discussion about how physicians are navigating the numerous treatment options and management strategies available to patients with advanced renal cell carcinoma (RCC). The discussion includes a review of the biologic pathways involved in RCC, a look at the plethora of new data for first-line and subsequent-line therapies coming out of the ASCO 2021 Annual Meeting, and a discussion on guiding patients through treatment decisions.

Video 1: Overview: Biology of RCC

In this video, the panel discusses the rationale for targeting different pathways such as VEGF, HIF-2, PI3-kinase, mTOR, PD-1, and CTLA4 in RCC treatment. They also touch on the active surveillance method and what factors to consider when guiding patients through treatment decisions.

Up Next

Video 1: Overview: Biology of RCC
Video 2: Selecting first-line treatment
Video 3: Subsequent-line therapy options
Video 4: Progressive disease and post-nephrectomy treatment options

About the Panel

Dr. Lalani Photo

Aly-Khan A. Lalani, MD, BSc

  • Assistant Professor, Department of Oncology
  • McMaster University
  • Staff Medical Oncology, Juravinski Cancer Centre
  • Calgary, Canada
Dr. Braun Photo

David A. Braun, MD, PhD

  • Instructor, Department of Medicine
  • Harvard Medical School
  • Physician, Department of Medical Oncology
  • Lank Center for Genitourinary Oncology
  • Dana-Farber Cancer Institute
  • Boston, Massachusetts
Dr. McGregor Photo

Bradley A. McGregor, MD

  • Clinical Director
  • Lank Center for Genitourinary Oncology
  • Dana-Farber Cancer Institute
  • Boston, Massachusetts
Disclosures

Aly-Khan A. Lalani, MD, BSc, has disclosed no relevant financial relationships.

David A. Braun, MD, PhD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Exelixis; LM Education/Exchange Service.

Bradley A. McGregor, MD, has disclosed no relevant financial relationships.